Boston Scientific Stock Slides Amid Weakness in Watchman Product Line
Boston Scientific (NYSE: BSX) stock fell by approximately 15% week-to-date due to management's admission of stagnation in the company’s Watchman heart implant product line and bearish analyst adjustments. CEO Mike Mahoney indicated flat revenue for this segment, citing a shift toward combined procedures rather than standalone ones.
